1. Home
  2. Programs
  3. Practical Neurology: Focus on Multiple Sclerosis
advertisement

MS Minute: Mood Disorders and Multiple Sclerosis

Individuals with MS are at twice the risk of suicide than the general population, so it’s vital for clinicians to screen for depression and to provide various treatment options.

12/12/2023
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
  • References

    1. Trivedi MH. Major depressive disorder in primary care: strategies for identification. J Clin Psychiatry. 2020;17;81(2):UT17042BR1C. doi: 10.4088/JCP.UT17042BR1C

    2. Boeschoten RE, Braamse AMJ, Beekman ATF, et al. Prevalence of depression and anxiety in multiple sclerosis: a systematic review and meta-analysis. J Neurol Sci. 2017;15;372:331-341. doi: 10.1016/j.jns.2016.11.067

    3. Masuccio FG, Gamberini G, Calabrese M, Solaro C. Imaging and depression in multiple sclerosis: a historical perspective. Neurol Sci. 2021;42(3):835-845. doi: 10.1007/s10072-020-04951-z

    4. Makhani N, Tremlett H. The multiple sclerosis prodrome. Nat Rev Neurol. 2021;17(8):515-521. doi: 10.1038/s41582-021-00519-3

    5. Wijnands JM, et al. Five years before multiple sclerosis onset: phenotyping the prodrome. Mult Scler. 2019;25:1092–1101

    6. Feinstein A, Pavisian B. Multiple sclerosis and suicide. Mult Scler. 2017;23(7):923-927. doi: 10.1177/1352458517702553

    7. Kroenke K, Spitzer RL, Williams JB. The patient health questionnaire-2: validity of a two-item depression screener. Med Care. 2003;41(11):1284-92. doi:

    10.1097/01.MLR.0000093487.78664.3C

    8. National Collaborating Centre for Mental Health (UK). Common Mental Health Disorders: Identification and Pathways to Care. Leicester (UK): British Psychological Society (UK); 2011. (NICE Clinical Guidelines, No. 123.) Appendix 13, Generalized anxiety disorder scale (2 items): https://www.ncbi.nlm.nih.gov/books/NBK92248/#

    9. Cordeau D, Courtois F. Sexual disorders in women with MS: assessment and management. Ann Phys Rehab Med. 2014;57(5);337-347

    10. Nathoo N, Mackie A. Treating depression in multiple sclerosis with antidepressants: a brief review of clinical trials and exploration of clinical symptoms to guide treatment decisions. Mult Scler Rel Dis. 2017;18:177-180

    11. Patten SB. Current perspectives on co-morbid depression and multiple sclerosis. Expert Rev Neurother. 2020 Aug;20(8):867-874. doi: 10.1080/14737175.2020.1806062

    12. Petrak F, Herpertz S, Albus C, et al. Cognitive behavioral therapy versus sertraline in patients with depression and poorly controlled diabetes: the Diabetes and Depression (DAD) study: A randomized controlled multicenter trial. Diabetes Care. 2015;38(5):767-75. doi: 10.2337/dc14-1599

    13. Cuijpers P, Gentili C: Psychological treatments are as effective as pharmacotherapies in the treatment of adult depression: a summary from randomized clinical trials and neuroscience evidence. Res Psychother. 2017;13;20(2):273. doi: 10.4081/ripppo.2017.273

    14. Smith, PJ, Merwin RM. The role of exercise in management of mental health disorders: an integrative review. Ann Rev Med. 2021;27:72:45-62

    15. Dalgas U, Stenager E, Sloth M, Stenager E. The effect of exercise on depressive symptoms in multiple sclerosis based on a meta-analysis and critical review of the literature. Eur J Neuro Off J Eur Fed Neurol Soc. 2015;22:443-e34. doi: 10.1111/ene.12576

    16. Ensari I, Motl RW, Pilutti LA. Exercise training improves depressive symptoms in people with multiple sclerosis: results of a meta-analysis. J Psychosom Res. 2014;76:465–471. doi: 10.1016/j.jpsychores.2014.03.014

    17. Adamson BC, Ensari I, Motl RW. The effect of exercise on depressive symptoms in adults with neurological disorders: a systematic review and meta-analysis. Arch Phys Med Rehabil. 2015;96:1329

    18. McCarthy B, Bunn H, Santalucia M, et al. Dextromethorphan-bupropion (Auvelity) for the treatment of major depressive disorder. Clin Psychopharmacol Neurosci. 2023;30;21(4):609-616. doi: 10.9758/cpn.23.1081

    19. Spravato

    20. Goodwin GM, Aaronson ST, Alvarez O. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022;387(18):1637-1648 doi: 10.1056/NEJMoa2206443

    21. Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of psilocybin versus escitalopram for depression

  • Disclosures

    The authors report no disclosures

Recommended
Details
  • References

    1. Trivedi MH. Major depressive disorder in primary care: strategies for identification. J Clin Psychiatry. 2020;17;81(2):UT17042BR1C. doi: 10.4088/JCP.UT17042BR1C

    2. Boeschoten RE, Braamse AMJ, Beekman ATF, et al. Prevalence of depression and anxiety in multiple sclerosis: a systematic review and meta-analysis. J Neurol Sci. 2017;15;372:331-341. doi: 10.1016/j.jns.2016.11.067

    3. Masuccio FG, Gamberini G, Calabrese M, Solaro C. Imaging and depression in multiple sclerosis: a historical perspective. Neurol Sci. 2021;42(3):835-845. doi: 10.1007/s10072-020-04951-z

    4. Makhani N, Tremlett H. The multiple sclerosis prodrome. Nat Rev Neurol. 2021;17(8):515-521. doi: 10.1038/s41582-021-00519-3

    5. Wijnands JM, et al. Five years before multiple sclerosis onset: phenotyping the prodrome. Mult Scler. 2019;25:1092–1101

    6. Feinstein A, Pavisian B. Multiple sclerosis and suicide. Mult Scler. 2017;23(7):923-927. doi: 10.1177/1352458517702553

    7. Kroenke K, Spitzer RL, Williams JB. The patient health questionnaire-2: validity of a two-item depression screener. Med Care. 2003;41(11):1284-92. doi:

    10.1097/01.MLR.0000093487.78664.3C

    8. National Collaborating Centre for Mental Health (UK). Common Mental Health Disorders: Identification and Pathways to Care. Leicester (UK): British Psychological Society (UK); 2011. (NICE Clinical Guidelines, No. 123.) Appendix 13, Generalized anxiety disorder scale (2 items): https://www.ncbi.nlm.nih.gov/books/NBK92248/#

    9. Cordeau D, Courtois F. Sexual disorders in women with MS: assessment and management. Ann Phys Rehab Med. 2014;57(5);337-347

    10. Nathoo N, Mackie A. Treating depression in multiple sclerosis with antidepressants: a brief review of clinical trials and exploration of clinical symptoms to guide treatment decisions. Mult Scler Rel Dis. 2017;18:177-180

    11. Patten SB. Current perspectives on co-morbid depression and multiple sclerosis. Expert Rev Neurother. 2020 Aug;20(8):867-874. doi: 10.1080/14737175.2020.1806062

    12. Petrak F, Herpertz S, Albus C, et al. Cognitive behavioral therapy versus sertraline in patients with depression and poorly controlled diabetes: the Diabetes and Depression (DAD) study: A randomized controlled multicenter trial. Diabetes Care. 2015;38(5):767-75. doi: 10.2337/dc14-1599

    13. Cuijpers P, Gentili C: Psychological treatments are as effective as pharmacotherapies in the treatment of adult depression: a summary from randomized clinical trials and neuroscience evidence. Res Psychother. 2017;13;20(2):273. doi: 10.4081/ripppo.2017.273

    14. Smith, PJ, Merwin RM. The role of exercise in management of mental health disorders: an integrative review. Ann Rev Med. 2021;27:72:45-62

    15. Dalgas U, Stenager E, Sloth M, Stenager E. The effect of exercise on depressive symptoms in multiple sclerosis based on a meta-analysis and critical review of the literature. Eur J Neuro Off J Eur Fed Neurol Soc. 2015;22:443-e34. doi: 10.1111/ene.12576

    16. Ensari I, Motl RW, Pilutti LA. Exercise training improves depressive symptoms in people with multiple sclerosis: results of a meta-analysis. J Psychosom Res. 2014;76:465–471. doi: 10.1016/j.jpsychores.2014.03.014

    17. Adamson BC, Ensari I, Motl RW. The effect of exercise on depressive symptoms in adults with neurological disorders: a systematic review and meta-analysis. Arch Phys Med Rehabil. 2015;96:1329

    18. McCarthy B, Bunn H, Santalucia M, et al. Dextromethorphan-bupropion (Auvelity) for the treatment of major depressive disorder. Clin Psychopharmacol Neurosci. 2023;30;21(4):609-616. doi: 10.9758/cpn.23.1081

    19. Spravato

    20. Goodwin GM, Aaronson ST, Alvarez O. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022;387(18):1637-1648 doi: 10.1056/NEJMoa2206443

    21. Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of psilocybin versus escitalopram for depression

  • Disclosures

    The authors report no disclosures

Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free